The College has partnered with Pfizer on an exciting grant opportunity to improve the ability of allergy practitioners to manage moderate to severe atopic dermatitis. Several grants of up to $350,000 will be awarded.
The goal of this joint ACAAI and Pfizer RFP grant program is to support projects that offer a comprehensive educational intervention to improve the ability of allergy practitioners to manage moderate to severe atopic dermatitis and specifically, demonstrate their ability to:
- Diagnose moderate to severe atopic dermatitis in different skin types and specifically skin of color.
- Make informed selection of therapies available now and in the pipeline, while managing the safety of and duration of treatment with systemic agents.
- Provide personalized care appropriate for differences in age and ethnicity.
- Educate patients on their role in successful disease management.
The proposal deadline is October 28, 2021. An ACAAI review panel will make final grant decisions.